Storge makes a good point in relation to the recent breakout in share price being unattached to news - bullish investor presentations could only get Anteris so far.  A more important factor is perhaps the current scarcity (relative to the past) of its shares.  Anteris/Admedus has a long history of desperate capital raises where institutional shareholders have had incentive to dump into a pumped share price post-raise for a quick and generous profit.  The current bullish sentiment is likely both a cause and effect of a reversal of this trend.  There are presently 6.6 million shares outstanding with another 2 million and change in options being now in the money (as at Tues 2/02/2021 at least) at the $8 mark - a legacy of a previous captial raise.  There are further options at the $10 mark which were issued to the most recent insitutional shareholder.  With this tighter share registry, a re-alignment of institutional shareholder incentives, the fading spectre of an imminent captial raise, and some key announcements on the horizon the recent reversal of Anteris' share price fortunes seems less illogical.